Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it Two studies found that those who used it saw reduction in apnea events ...

(NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step forward ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

The drug Zepbound might not have the same name recognition as Ozempic, but it's another in the class to treat obesity and Type 2 diabetes. And like Ozempic and Wegovy, Zepbound has been in short ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...

WASHINGTON — The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug to get the green light to ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the ...